Zydus Cadila gets FDA nod for generic Letairis

Press enter to search
Close search
Open Menu

Zydus Cadila gets FDA nod for generic Letairis

By Sandra Levy - 04/01/2019
Zydus Cadila has received the Food and Drug Administration’s clearance for ambrisentan tablets in 5 mg and 10 mg dosage strengths.

The product is the generic of Gilead’s Letairis tablets.

It is used to treat high blood pressure in the lungs (pulmonary arterial hypertension).

Ambrisentan tablets had a market value of $943 million in 2018, according to the company.

The product will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad, the company said.

Related Topics